Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Traws Pharma (TRAW) Income from Continuing Operations (2016 - 2025)

Traws Pharma's Income from Continuing Operations history spans 14 years, with the latest figure at 7368000.0 for Q4 2025.

  • Quarterly results put Income from Continuing Operations at 7368000.0 for Q4 2025, down 39.6% from a year ago — trailing twelve months through Dec 2025 was 17875000.0 (up 87.45% YoY), and the annual figure for FY2025 was 17875000.0, up 87.45%.
  • Income from Continuing Operations for Q4 2025 was 7368000.0 at Traws Pharma, down from 4055000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 1249000.0 in Q2 2025 to a low of 123348000.0 in Q2 2024.
  • The 5-year median for Income from Continuing Operations is 4867000.0 (2021), against an average of 10833500.0.
  • The sharpest move saw Income from Continuing Operations tumbled 2575.66% in 2024, then soared 98.99% in 2025.
  • Year by year, Income from Continuing Operations stood at 3763000.0 in 2021, then plummeted by 52.38% to 5734000.0 in 2022, then rose by 22.18% to 4462000.0 in 2023, then fell by 18.29% to 5278000.0 in 2024, then crashed by 39.6% to 7368000.0 in 2025.
  • According to Business Quant data, Income from Continuing Operations over the past three periods came in at 7368000.0, 4055000.0, and 1249000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.